hrp0092p1-382 | Growth and Syndromes (to include Turner Syndrome) (2) | ESPE2019

Nutritional Requirements in Prader Willi Syndrome Children Treated with Growth Hormone Under Two Years of Age

Corripio Raquel , Franch Noemi , Couto Yolanda , Pérez Jacobo , Gabau Elisabeth , Capdevila Nuria , Rivera Josefa

Background: Prader Willi Syndrome (PWS) patients under treatment with growth hormone (GH) have a better body composition and cognitive performance than untreated patients. The 2013 guideline recommended to start this treatment as soon as possible, for that reason 14 toddlers have been included in our center. Classically a 25% decrease in the caloric intake of PWS patients has been recommended to avoid obesity. However, from clinical practice observation, w...

hrp0089p1-p166 | Growth & Syndromes P1 | ESPE2018

Safety and Effectiveness of Growth Hormone Treatment in Patients with Prader-Willi Syndrome under 2 Years of Age in a Reference Hospital

Corripio Raquel , Tubau Carla , Cahis Nuria , Perez Jacobo , Rivera Josefa , Gabau Elisabeth

Introduction: Growth hormone (GH) treatment was approved in 2000 for patients with Prader-Willi syndrome (PWS). The main reason for its use was the improvement in body composition. As a result of 2 fatal episodes, it was decided to initiate it from 2 years of age arbitrarily. Average age of real start: 4-6years. GH per se is not a risk factor for mortality in PWS. The 2013 guideline recommends to star it as soon as possible, preferably under 2 years of age, when obesity is est...

hrp0084p2-170 | Adrenals | ESPE2015

Usefulness of Salivary Cortisol Levels in Secondary Adrenal Insufficiency in Paediatric Population

Corripio Raquel , Perez Jacobo , Borras Ariadna , Capdevila Laura , Sanchez Judith , Rivera Josefa

Background: The main cause of secondary adrenal insufficiency (SAI) in children is prolonged treatment with exogenous corticosteroids. plasma cortisol (PC) levels after administration of ACTH is the most used indicator of adrenal function in clinical practice. However, salivary cortisol (SC) levels is emerging as an alternative technique in the diagnosis of adrenal pathology, especially useful in the paediatric population because it is a simple noninvasive test.<p class="a...

hrp0084p3-699 | Diabetes | ESPE2015

Continuous Intersticial Glucose Monitoring in Early Detection of Glucose Tolerance Abnormalities in Adolescents with Cystic Fibrosis

Perez Jacobo , Corripio Raquel , Belver David , Asensio Oscar , Bosque Montserrat , Rivera Josefa

Background: Cystic fibrosis-related diabetes (CFRD) and glucose abnormalities have a negative impact on pulmonary function and survival in cystic fibrosis (CF) patients. Oral glucose tolerance test (OGGT) is the screening test of choice for CFRD, although undetected high glucose levels can be missed with this test. The use of a continuous intersticial fluid glucose monitoring system (CGM) can be useful in these patients.Objective and hypotheses: To deter...

hrp0094p2-197 | Fat, metabolism and obesity | ESPE2021

Triponderal mass index for the categorisation of childhood obesity on the basis of 58.364 observations of 7.792 patients

Corripio Raquel , Alder Lorna , Perez Jacobo , Sanchez-Garvin Dunia , Rivera Josefa ,

Introduction: childhood obesity constitutes a relevant problem of public health. Body mass index (BMI) is the most used anthropometric parameter for its definition: >2 z-score deviation (SD) according to age and sex for reference charts. Recent studies have proposed triponderal mass index (TMI) to identify metabolic risk by obesity. TMI presents the advantage to be a constant value simplifying the calculations.Aims: determine the use...

hrp0094p2-288 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Comorbidities in Turner Syndrome patients controlled in our center since the 80’s

Corripio Raquel , Vargas Laura , Baena Neus , Garcia Emma , Perez Jacobo , Rivera Josefa ,

Introduction: Turner syndrome (TS) is a genetic condition with different phenotypic expressions depending on karyotype. Due to genetic prenatal testing, its prevalence is getting lower. The objective was to analyze the presence of different comorbidities associated with TS according to the karyotype and evaluate if there is follow-up in adulthood.Methods: Descriptive retrospective study including all the patients genetic...

hrp0095p2-149 | GH and IGFs | ESPE2022

Advancing personalised medicine for growth hormone delivery: mixed-methods participatory study of a next generation, smart auto-injector device

I Labarta José , Rivera-Romero Octavio , Fernández-Luque Luis , Keiser Matthew , Koledova Ekaterina

Background: Treatment of growth hormone deficiency (GHD) requires daily injections over multiple years. Novel technologies facilitate this by automating the injection process – thereby adding comfort and reducing anxiety. An always-connected device, enabled by mobile technologies, also facilitates the collection of injection data such that adherence information is available to healthcare professionals (HCPs) in real-time. In developing new solutions, it ...

hrp0089fc4.3 | GH &amp; IGFs | ESPE2018

The Reduction in Longitudinal Growth Induced By PAPP-A2 Deficiency is Associated with Reduced Body Weight, Increased Energy Expenditure and Behavior Modification

Suarez Juan , Rivera Patricia , Vargas Antonio , Rubio Leticia , de Fonseca Fernando Rodriguez , Chowen Julie , Argente Jesus

Background: Pregnancy associated plasma protein (PAPP)-A2 is an insulin-like growth factor (IGF) binding protein (BP) protease that regulates IGF-1 availability, affecting postnatal growth. We have recently reported the first mutations in human PAPP-A2 causing short stature and changes in bone size and mineral density. However, the IGF system is involved in diverse physiological functions and to date it is unknown how mutations in PAPP-A2, which significantly reduce f...

hrp0097p1-104 | GH and IGFs | ESPE2023

Healthcare professionals’ perceptions on the quality and evolution of digital health devices to support paediatric growth hormone therapy: Results of a French participatory study

Rivera-Romero Octavio , Perge Kevin , Cochet Solenn , Trouvin Marie-Agathe , Koledova Ekaterina

Background: Treatment of growth hormone deficiency (GHD) requires daily injections over many years. Connected digital health devices can facilitate GH treatment by automating the injection process, which reduces anxiety, and collecting injection data in real-time so that accurate adherence information is available to healthcare professionals (HCPs). In developing new digital health solutions, HCP perspectives should be considered.<strong...

hrp0097p1-293 | GH and IGFs | ESPE2023

Healthcare professionals’ perceptions on the quality and evolution of digital health devices to support paediatric growth hormone therapy: Results of a UK participatory study

Rivera-Romero Octavio , R Kapoor Ritika , Mathew Verghese , Tollerfield Sally , Shah Pratik , Banerjee Indraneel , Koledova Ekaterina

Background: Long-term treatment with recombinant human growth hormone (r-hGH) is often challenging for children and adolescents, their caregivers and healthcare professionals (HCPs), as treatment requires daily injections over several years. Connected digital health devices facilitate this by automating the injection process to improve comfort, reduce anxiety and collect GH treatment data so that accurate adherence information is available to HCPs in real-time...